Primary central nervous system lymphoma
Conditions
Interventions
Experimental group:R-MT-EA
Sponsors
The First Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
No minimum to 60 Years
Inclusion criteria
Inclusion criteria: 1) Age <= 60 years, regardless of gender; 2) Previously untreated patients with a confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) based on histopathology and immunohistochemistry, with no evidence of systemic lymphohematopoietic or other organ involvement upon thorough physical examination and auxiliary investigations, thus clearly diagnosed as primary central nervous system lymphoma (PCNSL); 3) Informed consent obtained from the patient and their family; written informed consent signed, with the patient voluntarily agreeing to participate in the study.
Exclusion criteria
Exclusion criteria: Participants who meet any of the following conditions will be excluded from the study: 1) Presence of any other active malignant tumor at the time of screening; 2) Known history of human immunodeficiency virus (HIV) infection or diagnosis of acquired immunodeficiency syndrome (AIDS); 3) Known allergy or hypersensitivity to the investigational product or any of its excipients; 4) Any other condition that, in the judgment of the investigator, may lead to early withdrawal from the study. These include, but are not limited to, serious comorbidities, significant laboratory abnormalities, or other factors (e.g., family or social circumstances) that may compromise subject safety or compliance with study procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate, ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall Survival,OS;Cause of Death;Safety; | — |
Countries
China
Contacts
Public ContactYunqian Li/Fengyan Jin
The First Hospital of Jilin University
Outcome results
None listed